Diarrhea-predominant irritable bowel syndrome (IBS-D) presents with recurrent abdominal pain, diarrhea and altered defecation habits. The review authors framed IBS-D as a disorder of disrupted brain–gut interaction and a dysregulated brain–gut neuro-immune axis. They positioned Zusanli (ST36) as an established acupoint for digestive complaints, invoking the traditional maxim often paraphrased as “for abdominal diseases, Zusanli is indicated.”
The paper is a literature review rather than a new randomized trial. Investigators summarized preclinical and clinical mechanistic studies that connect ST36 stimulation with improvements in visceral hypersensitivity, mucosal inflammation, epithelial barrier integrity and microbial-metabolite pathways. The authors reported symptomatic endpoints (reduced abdominal pain and diarrhea) in the context of mechanism-oriented studies, but the review did not present standardized clinical outcome metrics or new efficacy data aggregated across trials.
Authors reported that acupuncture at ST36 engages a multi-level circuit described as peripheral afferent → central integration → autonomic efferent. Short neural pathways are implicated; the review indicated that ST36 stimulation can shift the balance between vagal and sympathetic activity. That rebalancing was linked, in the cited literature, to downstream modulation of gut function.
The study team observed changes in central processing that relate to nociception and emotion. These central effects, the authors argued, may mediate reductions in visceral hypersensitivity and improve symptom perception. The review did not supply detailed electrophysiological circuit maps or specific neural recording data; it noted that direct circuit verification remains insufficient and is an evidence gap.
Data summarized in the review indicate several peripheral mechanisms that could explain clinical benefit. Acupuncture at ST36 was described as affecting brain–gut peptide signaling, including alterations in 5-hydroxytryptamine pathways reported in the literature. The authors reported that ST36 stimulation can suppress immune activation and reduce the release of inflammatory mediators in mucosal tissues.
Improvements in epithelial integrity were also attributed to ST36: investigators cited enhanced expression of tight-junction proteins and reductions in intestinal mucosal permeability after acupuncture interventions in experimental studies. These changes, the review suggested, would blunt ongoing mucosal immune activation and decrease afferent signaling that drives pain.
Microbiota-related pathways were covered as well. The authors noted that acupuncture may modulate gut microbial composition and metabolite profiles, linking those alterations to shifts in mucosal immunity and epithelial function. The review linked microbiota modulation to symptomatic relief, but it did not supply standardized microbiome endpoints or quantitative effect sizes from clinical cohorts.
Together, these neural, immune and microbial mechanisms were framed as interrupting a proposed “stress–inflammation–pain amplification” feedback loop. By attenuating each leg of that loop, ST36 stimulation was described as capable of reducing visceral hypersensitivity and clinical symptoms such as abdominal pain and diarrhea.
The authors explicitly listed limitations in the literature. They reported insufficient circuit-level verification: studies rarely combined precise neuroanatomical tracing or selective pathway blockade with functional readouts to prove causality. Stimulus parameter–effect relationships remain unclear; the review noted that frequency, intensity, duration and modality of stimulation are not standardized across studies, preventing dose–response conclusions.
Clinical protocols also lack standardization, according to the authors. The review pointed out heterogeneous trial designs and variable acupuncture regimens in the cited literature, which complicates comparative assessment and replication. The paper did not claim novel clinical efficacy endpoints or provide new pooled outcome data; instead, it positioned the mechanistic syntheses as a basis for future standardized trials.
The authors recommended that future work prioritize rigorous circuit verification, systematic exploration of stimulation parameters, and development of standardized clinical protocols that incorporate mechanistic biomarkers. Those biomarkers could include autonomic function measures, mucosal inflammatory markers, tight-junction protein expression and microbiome–metabolite profiles, although the review did not prescribe specific assays or thresholds.
Conflict of interest: the authors declared none. The review serves as a mechanism-focused synthesis linking Zusanli (ST36) stimulation to multiple biological systems relevant to IBS-D, and it ends by calling for targeted experimental and clinical work to validate the proposed pathways and standardize therapeutic application.